Now Playing
|Videos|June 20, 2023
The Current State of Management of Locally Advanced/Metastatic Urothelial Carcinoma
Author(s)Pedro C. Barata, MD, MSc
Expert perspectives on the current treatment paradigm for patients diagnosed with locally advanced or metastatic urothelial carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
4
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
5